Selank

Mechanism

Tuftsin analog associated with GABAergic modulation and anti-inflammatory effects.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Anxiety reduction
• Stress resilience
• Mood support

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

not on file — no primary pharmacokinetic study found.

Storage

Lyophilised: Stable at room temperature ~3 weeks; store desiccated below -18C. Reconstituted: 4C for 2-7 days; below -18C for future use; 0.1% HSA/BSA for long term; avoid freeze-thaw. — source. ProSpec technical datasheet. Supplier handling recommendation for research-grade lyophilate, not a per-compound stability study.

In sport (WADA 2026)

not recorded as a yes or no — not named; S0 turns on whether Russian approval counts at all times if S0 applies the list S0 asks for approval by ANY governmental regulatory health authority; Selank is registered in Russia. Outside Russia it is generally treated as S0. Status not determinable from the list text; check GlobalDRO.

Reported adverse effects

• Limited safety data outside Russian clinical use

  N/Aonset: N/Areversibility not on file

Literature on file 5

• review or editorial
  Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Phenibutan—an Illegal Food Supplement With Psychotropic Effects and Health Risks. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• animal in vivo
  Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. graded on: an animal model — “Rats”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.

What is circulated not evidence 6

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose ubiquitous contradicts the record

  250 to 500 mcg per administration, one to three times daily intranasally, giving daily totals of 500 to 1500 mcg, is the range converged on by dosing guides.

  250 to 500 micrograms per administration, one to three times daily, delivered intranasally.

  On the record The record holds 250-500 mcg per administration daily, and marks it unverified. The per-administration figures match exactly; what is not on file is the frequency. A daily total of 1500 mcg is three times the daily maximum the record implies.

  Source 1 · Source 2

• unverified community data dose common nothing on file either way

  A Russian generalised-anxiety protocol of 300 to 900 mcg three times daily as 0.15 per cent nasal drops for fourteen days is repeatedly cited as the clinical basis for community dosing.

  300 to 900 mcg three times daily as 0.15 percent nasal drops, continued for 14 days

  On the record Nothing on file. The record grades selank on an animal model and cites no Russian clinical protocol, no indication and no concentration. The document the community treats as the source of the dose is absent from the record.

  Source 1

• unverified community data titration common agrees with the record

  Fourteen-day courses with roughly a month between them is the standard cycling given.

  250 to 500 micrograms per administration, one to three times daily, delivered intranasally.

  On the record The record holds a cycle of 2 to 4 weeks. The two-week course matches the low bound; the one-month rest interval is not on file.

  Source 1 · Source 2

• unverified community data side effect common nothing on file either way

  Transient nasal irritation, occasional mild headache and rare metallic taste are the adverse events named, and guides state that sedation, cognitive impairment and withdrawal seen with benzodiazepines are not observed.

  The most commonly noted adverse event is transient nasal irritation, occasional mild headache, and rare dysgeusia (metallic taste).

  On the record The record holds one entry: 'Limited safety data outside Russian clinical use'. None of the three named effects is on file, and neither is the comparison with benzodiazepines. The record's single entry is the more accurate statement of what is known.

  Source 1

• unverified community data sourcing occasional agrees with the record

  Guides state that no completed FDA or EMA registered trial of Selank exists and that human safety data beyond thirty days does not exist.

  There are no completed Food and Drug Administration or European Medicines Agency registered clinical trials of Selank.

  On the record The record grades selank on an animal model, and its only safety entry is 'Limited safety data outside Russian clinical use'. The two statements agree, though the record does not hold the thirty-day boundary.

  Source 1

• unverified community data dose common nothing on file either way

  Subcutaneous Selank is sold and dosed alongside the nasal route in most vendor charts.

  250 to 500 micrograms per administration, one to three times daily, delivered intranasally.

  On the record The record lists 'Intranasal / Subcutaneous' and 'Intranasal' as routes, so the route itself is on file, but no route-specific dose and no half-life is on file. Nothing on file says whether a nasal dose and an injected dose are interchangeable, which every chart assumes.

  Source 1 · Source 2

Identity

PubChem CID 11765600 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 11765600, the identifier on this record.

Molecular weight

751.9

Molecular formula

C33H57N11O9

CAS number

129954-34-3

PubChem CID

11765600

InChI key

JTDTXGMXNXBGBZ-YVHUGQOKSA-N

Sequence

TKPRPGP

SMILES

C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N3CCC[C@H]3C(=O)O)N)O

InChI

InChI=1S/C33H57N11O9/c1-19(45)26(35)29(49)41-20(8-2-3-13-34)30(50)44-17-6-11-23(44)28(48)40-21(9-4-14-38-33(36)37)31(51)43-16-5-10-22(43)27(47)39-18-25(46)42-15-7-12-24(42)32(52)53/h19-24,26,45H,2-18,34-35H2,1H3,(H,39,47)(H,40,48)(H,41,49)(H,52,53)(H4,36,37,38)/t19-,20+,21+,22+,23+,24+,26+/m1/s1

Classified as

GABAergic Modulationmechanism

This is where calming and anxiety-related records point, so it is worth checking whether a record rests on a measured receptor action or on an animal behaviour test with a mechanism attached afterwards.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Intranasalroute

A nasal device delivers a fixed volume per spray, so concentration rather than syringe volume sets the amount per spray, and a mass figure on a record is not usable until you know how many actuations it was divided across.

Also called

• Selank
• Selank (Mood)

Listed prices 315

What 183 shops we track listed for Selank, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record